ArticleBiology direct2026
Resilient gut microbiome is linked to immune control in HIV-1 infection.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundHIV-1 affects millions of people globally, and in rare cases, individuals known as “elite controllers” (EC) maintain undetectable viral load without antiretroviral therapy (ART). Given the crucial role of the gut microbiota in maintaining immune system homeostasis, this study investigated its composition and functionality in people living with HIV (PLHIV) (including viremic individuals, ART-treated individuals, and ECs) and healthy donors (HD). Fecal samples were collected for quantification of short-chain fatty acids (SCFAs), 16S rRNA sequencing, and bioinformatic analysis of taxonomic and functional profiles.
resultsECs and HDs exhibited a similar microbiota, characterized by higher abundance of Bacteroidetes and species associated with anti-inflammatory profiles, such as Bacteroides vulgatus and Bacteroides uniformis, and greater ecological diversity. Viremic individuals (VR) showed predominance of Ruminococcus and Eubacterium hallii, both associated with inflammation and unfavorable clinical progression. SCFAs such as acetate, butyrate, and propionate increased HIV replication in vitro, suggesting a possible role in viral reactivation. Functional analysis revealed differences in bacterial metabolic profiles in PLHIV, primarily in carbohydrate and amino acid metabolism.
conclusionsThis study highlights the potential of the gut microbiota in modulating HIV-1 progression. Therapeutic strategies aimed at restoring an EC-like microbiota composition may contribute to viral control and reduction of inflammation in PLHIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.